Company
Senseonics
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
6
510(k), De Novo and PMA
Device trials
11
As lead sponsor, any status
Adverse event reports
3,732
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
Senseonics is on our public-company list (ticker SENS). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
SENS
Nasdaq · Senseonics Holdings, Inc.
Public float
$377M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$35.3M
Fiscal year ending Dec 31, 2025
Net income
-$69.1M
Fiscal year ending Dec 31, 2025
R&D spending
$31.6M
Fiscal year ending Dec 31, 2025
Cash
$47.8M
As of Sep 30, 2026
Long-term debt
$54.2M
As of Sep 30, 2026
Shares outstanding
54.8M
As of Nov 3, 2026
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| May 20, 2025 | Equity | $20.3M | $20.3M | 1 | Rule 506(b) | Form D ↗May 29, 2025 |
| Oct 28, 2024 | Equity | $16.0M | $16.0M | 1 | Rule 506(b)Agent: H.C. Wainwright & Co., LLCCommissions $1.0M | Form D ↗Nov 8, 2024 |
| Aug 14, 2020 | Equity | $3.0M | $30.0M | 2 | Rule 506(b) | Form D ↗Sep 1, 2020 |
4 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- Senseonics Holdings, Inc.; Senseonics, Inc
- Headquarters
- Germantown, Maryland
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- $5,000,001 - $25,000,000
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1616543 ↗, CIK 1032158 ↗
Executives, directors and promoters
As listed on the latest Form D.
13 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense AP CGM SystemNew device typeDe Novo
DEN230052 · Decided Apr 29, 2024 · 264 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring (CGM) SystemPMA supplement
P160048-S021 · Decided Mar 29, 2023 · 180 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07386340 · 80 participants (planned) · Start Dec 29, 2025 · Primary completion Dec 2027
Device: Continuous Glucose Monitoring System · For: Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Escondido, California
- ROME GS System StudyRecruiting
NCT07518004 · 60 participants (planned) · Start Feb 12, 2026 · Primary completion Aug 2028
Device: Continuous Glucose Monitoring System · For: Diabetes; Diabetes Melletus, Type 1; Diabetes Mellitus, Type 2
Sites: Escondido, California; Walnut Creek, California; San Antonio, Texas · 4 sites in all
- Eversense® Non-adjunctive Use Post Approval StudyActive, not recruiting
NCT04836546 · 925 participants (planned) · Start Apr 13, 2021 · Primary completion Mar 31, 2026
Device: Blood glucose meter; Eversense CGM System · For: Diabetes
Sites: Los Angeles, California; Englewood, Colorado; Hamden, Connecticut · 23 sites in all
8 more trials with a free account
Reports received
3,732
Received Nov 1, 2025 to Nov 20, 2026. Includes 18 of another or unstated type.
Malfunction reports
2,911
78% of reports
Injury reports
802
21% of reports
Death reports
1
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 16 | 142 | 0 | 0 |
| Jan 24 | 71 | 206 | 0 | 0 |
| Feb 24 | 53 | 82 | 0 | 0 |
| Mar 24 | 126 | 184 | 0 | 0 |
| Apr 24 | 21 | 42 | 0 | 0 |
| May 24 | 37 | 41 | 0 | 0 |
| Jun 24 | 22 | 27 | 0 | 0 |
| Jul 24 | 23 | 37 | 0 | 0 |
| Aug 24 | 21 | 32 | 0 | 0 |
| Sep 24 | 24 | 33 | 0 | 0 |
| Oct 24 | 30 | 36 | 0 | 0 |
| Nov 24 | 26 | 49 | 0 | 0 |
| Dec 24 | 34 | 38 | 0 | 0 |
| Jan 25 | 33 | 50 | 0 | 0 |
| Feb 25 | 123 | 34 | 0 | 0 |
| Mar 25 | 78 | 54 | 0 | 0 |
| Apr 25 | 65 | 52 | 0 | 0 |
| May 25 | 82 | 72 | 0 | 0 |
| Jun 25 | 87 | 56 | 0 | 0 |
| Jul 25 | 130 | 43 | 0 | 0 |
| Aug 25 | 128 | 54 | 0 | 0 |
| Sep 25 | 110 | 50 | 0 | 0 |
| Oct 25 | 130 | 44 | 0 | 0 |
| Nov 25 | 108 | 53 | 0 | 0 |
| Dec 25 | 111 | 62 | 0 | 0 |
| Jan 26 | 95 | 58 | 0 | 0 |
| Feb 26 | 165 | 48 | 0 | 0 |
| Mar 26 | 338 | 83 | 1 | 0 |
| Apr 26 | 406 | 101 | 0 | 0 |
| May 26 | 279 | 78 | 0 | 0 |
| Jun 26 | 267 | 62 | 0 | 0 |
| Jul 26 | 316 | 46 | 0 | 2 |
| Aug 26 | 254 | 56 | 0 | 1 |
| Sep 26 | 254 | 60 | 0 | 9 |
| Oct 26 | 318 | 95 | 0 | 6 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- EVERSENSE SENSOR3,628
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0251-2020 · Started Sep 18, 2019
Reason given: Eversense Sensors have prematurely stopped functioning due to inadequate hydration of the sensor s glucose-sensing surface
Cause as FDA categorized it: Process control · Device type: Sensor, Glucose, Implanted, Non-Adjunctive Use (QHJ)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.